SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Condition:   Triple-negative Breast Cancer Intervention:   Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin Sponsor:   Henan Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials